. 2022 Apr 13;19(8):4705. doi: 10.3390/ijerph19084705

Table 12.

Estimated ORs (95% CI) for PCB congener levels in subjects with the combined risk factors for PAH compared to control by LOD 50th to 75th percentile and ≥75th percentile.

Analyte ¹	Controls (n)	Subjects with Combined Risk Factors for PAH (n)	Unadjusted OR (95% CI)	Adjusted OR ² (95% CI)	Adjusted OR ³ (95% CI)	Adjusted OR ⁴ (95% CI)
PCB074
50−75%	725	92	2.70 (2.69–2.71)	3.02 (3.01–3.04)	1.94 (1.93–1.95)	2.18 (2.17–2.19) ^a
≥75%	681	131	4.32 (4.31–4.34)	5.82 (5.79–5.84)	1.98 (1.78–1.99)	2.65 (2.63–2.66) ^a
PCB099
50−75%	953	73	1.77 (1.76–1.77)	1.78 (1.77–1.78)	1.38 (1.37–1.38)	1.40 (1.40–1.41) ^a
≥75%	892	127	3.00 (2.99–3.01)	3.18 (3.17–3.19)	1.52 (1.51–1.52)	1.62 (1.61–1.63) ^a
PCB118
50−75%	737	76	1.81 (1.80–1.82)	1.93 (1.92–1.94)	1.34 (1.34–1.36)	1.43 (1.42–1.44) ^a
≥75%	674	135	3.55 (3.53–3.57)	4.37 (4.35–4.39)	2.55 (2.54–2.56)	2.20 (2.56–2.59) ^a
PCB138
50−75%	941	82	1.82 (1.81–1.83)	1.84 (1.83–1.85)	1.21 (1.21–1.22)	1.22 (1.21–1.23) ^a
≥75%	896	132	2.67 (2.66–2.68)	2.74 (2.73–2.75)	1.37 (1.37–1.38)	1.37 (1.36–1.38) ^a
PCB153
50−75%	938	88	1.98 (1.97–1.99)	1.99 (1.99–2.00)	1.42 (1.41–1.43)	1.43 (1.42–1.44) ^a
≥75%	897	131	2.46 (2.45–2.47)	2.49 (2.48–2.50)	1.30 (1.30–1.31)	1.26 (1.25–1.27) ^a
PCB180
50−75%	935	90	1.75 (1.75–1.76)	1.75 (1.74–1.76)	1.31 (1.31–1.32)	1.29 (1.28–1.29) ^a
≥75%	897	128	2.32 (2.31–2.33)	2.26 (2.25–2.27)	1.51 (1.50–1.52)	1.33 (1.32–1.34) ^a

¹ Lipid adjusted and log-transformed polychlorinated biphenyls (ng/g); ² Adjusted for gender; ³ Adjusted for age, race, and BMI. ⁴ Adjusted for age, race, BMI, gender; ^a p < 0.05.